Medical Condition News

RSS

Single-dose of psilocybin shows long-term relief for depression in cancer patients

New results from a clinical trial reveal that a single dose of psilocybin-a naturally occurring psychedelic compound found in mushrooms-can provide sustained reductions in depression and anxiety in individuals with cancer suffering from major depressive disorder.

16 Jun 2025

Two existing medications work effectively together in treating alcohol use disorder

Two existing medications - one used for smoking cessation and the other for depression - appear to work effectively together in treating alcohol use disorder.

16 Jun 2025

Indiana University researcher helps develop FDA-approved Alzheimer’s test

A first-of-its-kind blood test to detect amyloid plaques in the brain associated with Alzheimer's disease recently received clearance from the U.S. Food and Drug Administration. An Indiana University School of Medicine researcher who helped lead the discovery and development of one of the biomarkers the test identifies hopes it will provide greater access and a more accurate diagnosis for patients.

16 Jun 2025

‘Not accountable to anyone’: As insurers issue denials, some patients run out of options

By the time Eric Tennant was diagnosed in 2023 with a rare cancer of the bile ducts, the disease had spread to his bones. He weighed 97 pounds and wasn't expected to survive a year with stage 4 cancer.

16 Jun 2025

A revolutionary drug for extreme hunger offers clues to obesity’s complexity

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction.

16 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

New insights into gout management strategies and cardiovascular outcomes

The European Alliance of Associations for Rheumatology - recommends that serum urate should be maintained at <6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout.

15 Jun 2025

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

15 Jun 2025

Tumor collagen structure may help explain racial disparities in cancer outcomes

In cancer care, accurate tools for predicting whether a tumor will spread (metastasize) can help patients receive the most appropriate treatments.

15 Jun 2025

Cardiovascular deaths surge among less educated Americans

About 525,000 more deaths occurred among US adults in 2023 than would be expected had pre-2010 mortality trends continued. More than 90 percent of these deaths occurred among individuals without a Bachelor's degree and were largely caused by cardiovascular diseases, underscoring how educational attainment can influence individuals' health opportunities and outcomes.

14 Jun 2025

c-Fos exhibits a dual role in memory formation and Alzheimer's disease

Immediate-early genes (IEGs), including c-Fos, are integral to the brain's response to stimuli. Initially identified as a proto-oncogene, c-Fos is essential for neural activity, synaptic plasticity, and stress responses.

14 Jun 2025

Researchers identify cellular hotspots that trigger ferroptosis

Researchers at the VIB-KU Leuven Center for Cancer Biology have uncovered how a unique interaction between two cellular compartments, namely the endoplasmic reticulum (ER) and mitochondria, can act as a central ignition point for ferroptosis, a form of cell death driven by lipid oxidation and iron.

14 Jun 2025

Osteoarthritis treatment in practice falls short of EULAR guidelines

Osteoarthritis is a leading cause of chronic pain, often affecting physical function, daily activities, and quality of life.

14 Jun 2025

Vaccination linked to better kidney outcomes in hospitalized COVID-19 patients

Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests.

14 Jun 2025

Understanding the role of astrocytes in depression and neuroinflammation

Major depressive disorder (MDD) is a mental health condition that negatively affects the mood of a person and causes a loss of interest in activities that were previously associated with happiness.

13 Jun 2025

Rising T1DE and Lurie Children’s collaborate to scale precision diabetes management

The Rising T1DE Alliance (Rising T1DE), a national collaborative spearheading innovation in type 1 diabetes care, is transforming how healthcare systems leverage data, technology, and collaboration to drive improved patient outcomes.

13 Jun 2025

Advancing precision oncology in intrahepatic cholangiocarcinoma

ICCA accounts for 10–15% of primary liver cancers and is notorious for late-stage diagnosis and resistance to chemotherapy and radiotherapy.

13 Jun 2025

Boosting CAR T cell survival to improve solid tumor therapy

Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.

13 Jun 2025

Empagliflozin preserves kidney function in heart attack patients

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease.

13 Jun 2025

New drug combination shows high remission rates in acute myeloid leukemia

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.

13 Jun 2025